AtriCure Announces Proposed Public Offering of Common Stock
May 11 2020 - 7:16AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments
for atrial fibrillation (Afib) and left atrial appendage (LAA)
management, today announced it has commenced a proposed
underwritten public offering in which it expects to issue and sell
approximately $100 million of shares of its common stock pursuant
to its existing automatic shelf registration statement. In
connection with this offering, AtriCure plans to grant the
underwriters of the offering a 30-day option to purchase up to an
additional 15% of the shares of its common stock at the public
offering price less the underwriting discounts and commissions.
AtriCure intends to use the net proceeds from the offering for
working capital and other general corporate purposes, which may
include repayment of debt or long-term liabilities, and other
potential corporate or market development activities.
J.P. Morgan and Piper Sandler are acting as joint book-running
managers for the offering. Canaccord Genuity, Needham &
Company, Stifel, SVB Leerink and BTIG are acting as co-managers.
The offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or
the actual size or terms of the offering.
The securities described above are being offered by AtriCure
pursuant to an automatic shelf registration statement previously
filed with the Securities and Exchange Commission (SEC) on March 1,
2019. The offering is being made only by means of a written
prospectus and prospectus supplement that form a part of the
registration statement. A preliminary prospectus supplement
relating to the offering has been filed with the SEC and is
available on the SEC’s website at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus,
when available, may also be obtained by contacting J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by phone at
1-866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; or
Piper Sandler & Co., Attention: Prospectus Department, 800
Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at
800-747-3924, or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first and only
medical device to receive FDA approval for the treatment of
persistent Afib. AtriCure’s AtriClip Left Atrial Appendage
Exclusion System products are the most widely sold LAA management
devices worldwide.
Forward-Looking Statements
This announcement contains forward-looking statements, including
statements relating to AtriCure’s expectations regarding the
completion, timing and size of the proposed public offering and use
of proceeds. These statements are subject to significant risks and
uncertainties; actual results could differ materially from those
projected and AtriCure cautions investors not to place undue
reliance on the forward-looking statements contained in this
release. These risks and uncertainties include, without limitation,
risks and uncertainties related to market conditions and
satisfaction of customary closing conditions related to the public
offering. There can be no assurance that AtriCure will be able to
complete the public offering on the anticipated terms, or at all.
Risks and uncertainties relating to AtriCure and its business can
be found in AtriCure’s Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q filed with the SEC which contain risk factors.
Risk factors are also contained in the preliminary prospectus
supplement filed with the SEC with respect to the offering.
AtriCure undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events, changes in AtriCure’s expectations
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200511005475/en/
Andy Wade AtriCure, Inc. Chief Financial Officer (513) 755-4564
awade@atricure.com
Lynn Pieper Lewis Gilmartin Group Investor Relations (415)
937-5402 lynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Apr 2023 to Apr 2024